The National Pharmaceutical Council has named John O’Brien, a Trump-HHS point person on drug pricing , as its new president and CEO. “John brings to NPC a keen understanding of the issues facing both health care and the innovative biopharmaceutical industry, as well as a deep understanding of the important role NPC plays within the broader health care environment,” NPC Board of Director Chair Michael Ryan said in a statement Friday. O’Brien is expected to start June 1, replacing interim...